Business Wire

AFC Energy launches Hyamtec Limited (“Hyamtec”) to unlock the global hydrogen value chain

Share

Delivering next generation Ammonia Cracking Technology

Hyamtec, the UK’s newest hydrogen company, has been launched by AFC Energy plc to deliver next generation modular ammonia cracking technology.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240918101995/en/

Aerial view of ammonia cracker site (Photo: Business Wire)

Hyamtec can make on-site, on-demand hydrogen at just 10% of the cost of truck delivered hydrogen and will prioritise natural gas displacement in the hard to abate heavy industrial sectors which account for 50% of global carbon emissions.

Hyamtec will target areas which represent a £40 billion market in the UK alone:

  • Hydrogen rich combustible fuel gas for the decarbonisation of industrial heat generation;
  • Ammonia conversion of large combustion engines for power generation, marine and mining; and
  • Modular purified hydrogen production for fuel cells and transportation.

Hydrogen is the solution for decarbonisation of heavy industry and green hydrogen plants will dominate new capacity and by 2030, up to 20% of hydrogen produced globally will be green. This production will be located where the renewable energy required is abundant plentiful and cheap; however, hydrogen is difficult to store and transport, and it will take decades to install hydrogen pipelines. To transport the hydrogen to where it will be used, typically thousands of miles away, will require it to be moved as ammonia and then converted back to hydrogen.

Hyamtec’s technology can achieve this on-site at the lowest cost and highest efficiency to provide a solution to unlock industrial decarbonisation at scale. Hyamtec crackers have proven their ability to integrate with ammonia combustion engines (as a pilot fuel) and to deliver ISO Grade hydrogen for use in fuel cell applications.

Dr. Mike Rendall, Managing Director of Hyamtec Limited, said:

“Hyamtec is focused on fast tracking the decarbonisation of industry through ammonia and our ammonia cracking technologies. With over £40bn spent per annum on natural gas by industrial users in the UK alone, the global opportunity to displace fossil fuels in industry with ammonia is immense.

“The global journey to net zero will require the rapid development of hydrogen-based technologies. We look forward to partnering with industry to support the rapid decarbonisation of the world’s hardest to abate sectors and to announcing Hyamtec’s first commercial deals soon.”

Find out more at www.hyamtec.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20240918101995/en/

Contacts

Hyamtec Ltd

Hyamtec Ltd
Mike Rendall, Managing Director
+44 (0) 14 8327 6726
FTI Consulting – PR Advisors
afcenergy@fticonsulting.com

afcenergy@fticonsulting.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM31.8.2025 11:15:00 CEST | Press release

− Sustained Benefit of Vutrisiran Across Mortality, Cardiovascular Events, Quality of Life and Cardiac Biomarkers Observed Through Up to 48 Months, Including 12 Months from the Ongoing Open-Label Extension, Reinforce Potential as First-Line Treatment for ATTR-CM –− Vutrisiran, which Delivers Rapid Knockdown of Transthyretin, Reduced the Risk of Composite of All-Cause Mortality or First Cardiovascular Event by 37% in the Overall Population and 42% in the Monotherapy Group During the Same Period – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced results of new analyses from the HELIOS-B Phase 3 study of AMVUTTRA® (vutrisiran), an RNAi therapeutic approved for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults. Data from the 12-month follow-up of the ongoing open-label extension (OLE) period of HELIOS-B were presented during an oral session at the European Society of Card

WETEX Opens Broad Investment Horizons for International Companies31.8.2025 08:30:00 CEST | Press release

DEWA will organise the exhibition from 30 September to 2 October 2025 Under the directives of HH Sheikh Mohammed bin Rashid Al Maktoum, Vice President and Prime Minister of the UAE and Ruler of Dubai, and the patronage of HH Sheikh Ahmed bin Saeed Al Maktoum, Chairman of the Dubai Supreme Council of Energy, Dubai Electricity and Water Authority (DEWA) will organise the 27th edition of the Water, Energy, Technology and Environment Exhibition (WETEX) from 30 September to 2 October 2025 at the Dubai World Trade Centre. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250830023664/en/ WETEX opens broad investment horizons for international companies (Photo: AETOSWire) WETEX embodies the UAE's pioneering position in clean and renewable energy and sustainability. It also supports Dubai's ambitious vision of a sustainable economy. The exhibition covers multiple areas including water, energy, smart cities, green mobility, artificial i

Daiichi Sankyo Announces the Initiation of the Development of Oral Triple Combination Lipid-Lowering Tablets to Support the Management of LDL-C30.8.2025 18:00:00 CEST | Press release

Initiation of the development of new oral triple combination tablets, aimed at improving adherence and outcomes in low-density lipoprotein cholesterol (LDL-C) management. Recent findings from MILOS and SANTORINI registries presented at ESC Congress 2025, highlight ongoing challenges in accurately assessing cardiovascular (CV) risk and helping patients reach LDL-C targets.1-5 Furthermore, data from a four-country cohort of the MILOS study support the real-world effectiveness and safety of bempedoic acid in both sexes.6 Simulation using SANTORINI data reveals the potential of improved LDL-C goal attainment with tailored oral combination therapy of statins, ezetimibe and bempedoic acid, in line with the latest 2025 Focused Update of the 2019 ESC/EAS Guidelines for the management of dyslipidaemias.7,8 Daiichi Sankyo has a long-standing commitment to easing treatment of cardiovascular disease (CVD) and exploring new treatment options that improve CVD outcomes and treatment adherence. Daiich

Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial30.8.2025 16:30:00 CEST | Press release

- Phase 3 Trial Informed by KARDIA-3 Phase 2 Study Results Presented as a Late-Breaking Abstract at the European Society of Cardiology Congress 2025 -- Zilebesiran Demonstrated Clinically Meaningful Reductions in Office Systolic Blood Pressure in Patients with Uncontrolled Hypertension and High Cardiovascular Risk at Month 3 Primary Endpoint, with Continuous Control Through Month 6 -- Zilebesiran Displayed Encouraging Safety When Combined with Two or More Antihypertensives -- Results Support Biannual Dosing Regimen and Inform Phase 3 Trial Design: Trial Expected to Initiate by Year-End 2025 -- Alnylam to Host Webcast Investor Event on August 30, 2025, at 1:00 pm ET (7:00 pm CEST) - Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, today announced plans to initiate a Phase 3 cardiovascular outcomes trial (CVOT) to evaluate the potential of zilebesiran to reduce the risk of major adverse cardiovascular events. This decision is informed by results from t

Andersen Consulting styrker sine kompetencer inden for virksomhedstransformation med Fabric29.8.2025 17:01:00 CEST | Pressemeddelelse

Andersen Consulting udvider sin platform gennem en samarbejdsaftale med Fabric, der er et strategisk designfirma, der arbejder med organisationer for at integrere bæredygtighed, forsyningskæder og menneske-centreret innovation på tværs af kultur og drift. Fabric blev grundlagt i Japan i 2021 og arbejder sammen med virksomheder og globale brands om at skabe regenerative forretningsmodeller sammen samt bæredygtige brandstrategier og fremtidssikrede produkter. Ved hjælp af strategiske designmetoder og designfilosofi skaber virksomheden indsigtsbaseret transformation på tværs af forsyningskæder, brand og HR. Fabric er kendt for sin systemtænkning og sit engagement i social og miljømæssig bæredygtighed og fremmer desuden digitale transformationsinitiativer, der integrerer bæredygtighed, humankapital og AI. "Fabric er skabt for at hjælpe virksomheder med at blomstre gennem regenerative relationer til mennesker, samfund og forbundne, levende systemer," sagde James Hollow, der er grundlægger a

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye